Creating a new generation of small molecule protease inhibitors

KalVista Pharmaceuticals is focused on the discovery, development, and commercialization of small molecule protease inhibitors as new treatments for diseases with significant unmet needs. KalVista has developed a proprietary portfolio of novel, small molecule plasma kallikrein inhibitors initially targeting hereditary angioedema (HAE) and diabetic macular edema (DME). KalVista has created a structurally diverse portfolio of oral plasma kallikrein inhibitors from which it plans to select multiple drug candidates to advance into clinical trials for HAE. In October 2017, KalVista announced a deal with Merck for $37 million upfront and milestone payments of up to $715 million, in addition to acquiring a 9.9% ownership stake.

Visit Site

Related Press